Full-Life Technologies Announces U.S. FDA IND Clearance and Australian Regulatory Clearance for [²²⁵Ac]Ac-FL-261 Phase 1 Clinical Trial

Full-Life Technologies Announces U.S. FDA IND Clearance and Australian Regulatory Clearance for [²²⁵Ac]Ac-FL-261 Phase 1 Clinical Trial

LONDON, Sept. 9, 2026 /PRNewswire/ -- Full-Life Technologies ("Full-Life", the "Company"), a privately held, fully integrated, clinical-stage actinium-based global radiopharmaceutical company, today announced that the U.S. Food and Drug...

Harbour BioMed Announces U.S. FDA IND Clearance for HBM7004 for the Treatment of Advanced Solid Tumors

Harbour BioMed Announces U.S. FDA IND Clearance for HBM7004 for the Treatment of Advanced Solid Tumors

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, May 8, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in...

GenEditBio Receives FDA Clearance of IND Application for Its Lead In Vivo Genome-Editing Program GEB-101 for TGFBI Corneal Dystrophy

GenEditBio Receives FDA Clearance of IND Application for Its Lead In Vivo Genome-Editing Program GEB-101 for TGFBI Corneal Dystrophy

HONG KONG, Jan. 5, 2026 /PRNewswire/ -- GenEditBio Limited ("GenEditBio"), a clinical-stage biotechnology startup focusing on genome-editing therapeutic solutions, today announced that the U.S. Food and Drug Administration (FDA) has cleared the...

Fapon Biopharma Publishes Pioneering Research in Cell Reports Medicine on FP008, an anti-PD 1 X IL-10M Fusion Protein for Cancer Immunotherapy

Fapon Biopharma Publishes Pioneering Research in Cell Reports Medicine on FP008, an anti-PD 1 X IL-10M Fusion Protein for Cancer Immunotherapy

DONGGUAN, China, Dec. 23, 2025 /PRNewswire/ -- Fapon Biopharma, a biotech in developing therapeutic biologics including cytokine-antibody fusion proteins and T-cell engagers, announced the publication of pioneering research on FP008, a novel fusion...

Minghui Pharmaceutical Announces FDA clearance of IND to Initiate Global Phase Ⅲ Trials of MHB018A, a Subcutaneous Single-Domain IGF-1R Antibody, in Thyroid Eye Disease

Minghui Pharmaceutical Announces FDA clearance of IND to Initiate Global Phase Ⅲ Trials of MHB018A, a Subcutaneous Single-Domain IGF-1R Antibody, in Thyroid Eye Disease

SHANGHAI and HANGZHOU, China, Dec. 15, 2025 /PRNewswire/ -- Minghui Pharmaceutical, a late-stage biopharmaceutical company dedicated to developing transformative medicines in immunology and oncology, today announced the U.S. Food and Drug...

menu
menu